Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.
We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients.
Assembly is headquartered in South San Francisco.
We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients.
Assembly is headquartered in South San Francisco.
Location: United States, California, South San Francisco
Employees: 51-200
Founded date: 2014
Investors 2
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | MBC BioLab... | mbcbiolabs... |
Mentions in press and media 3
| Date | Title | Description |
| 19.12.2024 | Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs | —Assembly Bio to receive approximately $20.1 million equity investment and $10 million in accelerated funding under the collaboration, extending cash runway to mid-2026— —Additional equity investment raises Gilead’s ownership stake in Assem... |
| 11.09.2024 | Versatope Launches Clinical Development Team for VT-105, a Pan-influenza A Vaccine Candidate | LOWELL, Mass., Sept. 11, 2024 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today their new Chief Medical Officer, Dr. M.P. Anza Mammen, MD and the additio... |
| 17.06.2024 | Assembly Biosciences Announces $12.6 Million in Equity Financings | — Funding supports advancement of antiviral portfolio, including four candidates in clinical development, and extends cash runway into Q1 2026 — — Anticipated near term interim data read outs include ABI-5366 Phase 1a in 3Q24 and Phase 1b i... |